Speaker Profile
Ph.D., Global Head of Research, Kite Pharma
Biography
Dr. Hegde oversees clinical product development, cancer genomics, andearly-stage research, as well as regulatory and quality assurance, toaccelerate advancement of the Companys leading comprehensive genomicprofiling portfolio. She is passionate about innovation in cancer researchand translating innovations to precision medicine tools to advance care forpatients. Dr. Hegde has spent nearly two decades in the biopharmaceuticalindustry, with a proven track record in drug development, registration, andcommercialization of therapeutics with companion diagnostics in cancerimmunotherapy. Prior to joining Foundation Medicine, Dr. Hegde spent 12years at Genentech. Dr. Hegde served as senior director and principalscientist in oncology biomarker development at Genentech, during which sheestablished and led the biomarker group accountable for translationalscience strategies in cancer immunotherapy. Dr. Hegde was instrumental inthe approvals for atezolizumab in both the United States and EuropeanUnion, as well as its forthcoming diagnostic filings.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Priti Hegde, Kite Pharma
PMWC Award Ceremony
• Michel Sadelain, Columbia University
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia University
CAR-T Cell Therapies: Strategies in Mitigating Challenges in Solid Tumor Delivery
• Chair: David Barrett, Kite Pharma
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia University
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford University
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Royal Marsden
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• David Chang, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Aliya Omer, AstraZeneca
• Priti Hegde, Kite Pharma
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
• Fabian Gerlinghaus, Cellares
TCR-Based Cell Therapies: New Targets and Clinical Advances
• Chair: Diwakar Davar, UPMC
• Lauren Harshman, Clasp Therapeutics
• Cassian Yee, MD Anderson Cancer Center
Gene Editing & Synthetic Biology for Therapy
• Chair: Matthew Porteus, Stanford University
• Rachel Haurwitz, Caribou Biosciences
• Kole T. Roybal, Parker Institute
• Ken Drazan, ArsenalBio
In-Vivo Myeloid Programming: Engineering the Innate Immune System for Solid Tumor Therapy
• Daniel Getts, Create Medicines
Synthetic Circuits for Smarter Cell Therapies: Enhancing NK Precision and Persistence
• Gudrun Stengel, Alida Biosciences
